Robert Azelby
CIK 1656998 · President & CEO · last filed 2026-07-01
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
JUNO price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
DUBLIN, OH 43017
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| AUTL | Director | — | $1.38 | — | $0 | 1 | 2026-07-01 |
| TNGX | Director | 5,740 | $23.18 | $133.1K | $0 | 1 | 2026-06-23 |
| ADCT | Director | 112,805 | $1.72 | $194.0K | -$20.2K | 5 | 2026-06-03 |
| Terns Pharmaceuticals, Inc. (TERN) Delisted | Director | — | $52.95 | — | $0 | 3 | 2026-05-05 |
| CAH | Director | 4,085 | $261.93 | $1.07M | $0 | 3 | 2025-11-06 |
| CHINOOK THERAPEUTICS, INC. (KDNY) Delisted | Director | — | $40.39 | — | $0 | 2 | 2023-08-11 |
| Climb Bio, Inc. (ELYM) Delisted | President & CEO | — | $5.11 | — | $0 | 2 | 2022-11-02 |
| Clovis Oncology, Inc. (CLVS) Delisted | Director | — | $0.08 | — | $0 | 4 | 2021-06-11 |
| IMMUNOMEDICS INC (IMMU) Delisted | Director | 3,718 | — | — | $0 | 3 | 2020-10-23 |
| ALDER BIOPHARMACEUTICALS INC (ALDR) Delisted | President and CEO | — | — | — | $0 | 3 | 2019-04-25 |
| Juno Therapeutics, Inc. (JUNO) Delisted | EVP & Chief Commercial Officer | 0 | — | — | -$14.06M | 16 | 2018-03-07 |
| Cascadian Therapeutics, Inc. (CASC) Delisted | Director | — | — | — | $0 | 2 | 2017-06-13 |
Recent Filings · Page 5 of 5
48 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2017-10-20 | Juno Therapeutics, Inc. (JUNO) Delisted | Grant (A) | +35,893 | $0 | EDGAR |
| 2017-09-14 | Juno Therapeutics, Inc. (JUNO) Delisted | Sell (S) | −12,850 | -$577.6K | EDGAR |
| 2017-08-31 | Juno Therapeutics, Inc. (JUNO) Delisted | Sell (S) | −12,869 | -$514.1K | EDGAR |
| 2017-06-13 | Cascadian Therapeutics, Inc. (CASC) Delisted | Grant (A) | — | $0 | EDGAR |
| 2017-04-04 | Cascadian Therapeutics, Inc. (CASC) Delisted | Grant (A) | — | $0 | EDGAR |
| 2017-02-09 | Juno Therapeutics, Inc. (JUNO) Delisted | Grant (A) | +27,439 | $0 | EDGAR |
| 2016-11-10 | Juno Therapeutics, Inc. (JUNO) Delisted | Mixed | −2,921 | -$311.8K | EDGAR |
| 2015-11-02 | Juno Therapeutics, Inc. (JUNO) Delisted | Grant (A) | +38,640 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.